GW's cannabis-de­rived drug Epid­i­olex fi­nal­ly launch­es in the US with an av­er­age list price of $32,500

Fol­low­ing the keen­ly an­tic­i­pat­ed June ap­proval of its cannabis-de­rived Epid­i­olex, GW Phar­ma­ceu­ti­cals $GW­PH has fi­nal­ly launched the rare epilep­sy drug in the Unit­ed States …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER